Immune-Focused Drug Shows Promise Against Lung Cancer

TUESDAY, Dec. 13, 2016 — An immunotherapy drug called Tecentriq (atezolizumab) extended the survival of lung cancer patients for several months longer than chemotherapy and caused fewer side effects, according to a new study.
The findings are from…
Source: Topamax